Joni K. Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joni K. Evans has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Cody D. Blazek
Wake Forest University School of Medicine, Assistant Professor - Department of Orthopaedic Surgery & Rehabilitation, Secondary Appointment Assistant Professor - Department of Vascular and Endovascular Surgery, Atrium Wake Forest Baptist Medical Center, Winston-Salem, NC
5 shared publications Aaron T. Scott
Associate Professor, Department of Orthopaedic Surgery, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC
2 shared publicationsCourtney Bailey
Division of Gynecological Oncology, Medical College of Georgia, Augusta, GA
2 shared publications- David I. Shalowitz
West Michigan Cancer Center, Kalamazoo, MI
2 shared publications - Hayden L. Hoffler
Fellow, Southeast Permanente Foot & Ankle Trauma & Reconstructive Fellowship Program, The Southeast Permanente Medical Group, Atlanta, GA
2 shared publications - Jennifer A. Kipp
Department of Orthopaedic Surgery and Rehabilitation, Atrium Health Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in The Journal of Foot and Ankle Surgery
Evaluation of closure materials on outcomes following transmetatarsal amputation: A retrospective review
- 18 September 2026
- Published by Elsevier in The Journal of Foot and Ankle Surgery
Open AccessEvaluation of closure materials on outcomes following transmetatarsal amputation: A retrospective review
- 5 August 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Real-World Outcomes of Automated Insulin Delivery Use in Hospitalized Adults With Diabetes
Background: Automated insulin delivery (AID) systems are increasingly used by individuals living with diabetes in the outpatient setting, but data on their safety and effectiveness during hospitalizations remains limited. The objective is to evaluate the use and efficiency of AID systems in hospitalized adults with diabetes. Methods: We performed a retrospective cohort study based on electronic health record data from hospital admissions of 316 patients with diabetes using insulin pumps. Automated insulin delivery and continuous glucose monitor use, insulin pump continuation, length of stay (LOS), and glycemic outcomes among the cohort were analyzed. The primary aims of the study were to describe rates of insulin pump continuation and reasons associated with removal, and rates of pump reinitiation. Secondary outcomes included effects of insulin pump removal and prompt endocrinology consultation on inpatient glycemic outcomes and LOS. Results: Insulin pumps were continued in 64.2% of all admissions. The most common reason for pump discontinuation was surgery (30.1%). Length of stay was longer when pumps were removed (8.3 vs 4.7 days, P < .001) and when endocrinology consultation occurred more than 24 hours after admission ( P < .001). Insulin pump continuation was associated with lower hyperglycemia (glucose >180 mg/dL) rates without an increase in hypoglycemia (glucose <70 mg/dL) in both critical and noncritical care settings. Conclusions: Continuation of insulin pumps was associated with improvement in hyperglycemia without increased hypoglycemia risk and with shorter LOS in the hospital. Standardized institutional policies including prompt glycemic management team consultation may help expand safe continuation of AID during hospitalizations.
- 5 August 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Real-World Outcomes of Automated Insulin Delivery Use in Hospitalized Adults With Diabetes
Background: Automated insulin delivery (AID) systems are increasingly used by individuals living with diabetes in the outpatient setting, but data on their safety and effectiveness during hospitalizations remains limited. The objective is to evaluate the use and efficiency of AID systems in hospitalized adults with diabetes. Methods: We performed a retrospective cohort study based on electronic health record data from hospital admissions of 316 patients with diabetes using insulin pumps. Automated insulin delivery and continuous glucose monitor use, insulin pump continuation, length of stay (LOS), and glycemic outcomes among the cohort were analyzed. The primary aims of the study were to describe rates of insulin pump continuation and reasons associated with removal, and rates of pump reinitiation. Secondary outcomes included effects of insulin pump removal and prompt endocrinology consultation on inpatient glycemic outcomes and LOS. Results: Insulin pumps were continued in 64.2% of all admissions. The most common reason for pump discontinuation was surgery (30.1%). Length of stay was longer when pumps were removed (8.3 vs 4.7 days, P < .001) and when endocrinology consultation occurred more than 24 hours after admission ( P < .001). Insulin pump continuation was associated with lower hyperglycemia (glucose >180 mg/dL) rates without an increase in hypoglycemia (glucose <70 mg/dL) in both critical and noncritical care settings. Conclusions: Continuation of insulin pumps was associated with improvement in hyperglycemia without increased hypoglycemia risk and with shorter LOS in the hospital. Standardized institutional policies including prompt glycemic management team consultation may help expand safe continuation of AID during hospitalizations.
- 8 September 2025
- Published by SAGE Publications in Foot & Ankle International
- Vol. 46 (10) , 1083-1089
A Retrospective Cohort Study From 2 Academic Medical Centers: Oral vs Intravenous Antibiotics for Diabetic Osteomyelitis
Background: The Infectious Diseases Society of America guidelines recommend a prolonged course of antibiotics in the setting of residual osteomyelitis. More recently published literature suggests that oral antibiotics may offer comparable outcomes to intravenously administered antibiotics when treating orthopaedic infections. In a prior study, we investigated the outcomes of both routes of antibiotic administration in patients with diabetic foot infections at a single academic medical institution. Methods: The goal of this study is to retrospectively evaluate the therapeutic success in 196 patients receiving oral or intravenous antibiotics for treatment of residual infection following amputation at 2 academic medical centers. Treatment was considered successful if patients who completed a minimum of 4 weeks of antibiotic therapy had complete wound healing and did not require additional debridement or amputation within 1 year of their initial surgery. Results: After performing a retrospective chart review, no difference was determined in treatment success between patients who underwent oral or intravenous antibiotics at either WFBMC ( P = .34) or UPMC ( P = .99). No difference in success was found when combining institutional data ( P = .52). The median time to healing for oral antibiotics was 3.21 months compared with 3.85 months for intravenous ( P = .16). Reoperation rates did not differ among treatment types ( P = .53). Hemoglobin A 1c values were lower among patients with treatment success (8.6 ± 2.3) versus failure (9.5 ± 2.5) ( P = .016). Conclusion: This study supports the consideration of oral antibiotics as a viable option for selected diabetic patients with residual osteomyelitis. No significant differences were observed in treatment success, healing time, or reoperation rates, although the study was not powered to determine equivalence.
- 8 September 2025
- Published by SAGE Publications in Foot & Ankle International
- Vol. 46 (10) , 1083-1089
A Retrospective Cohort Study From 2 Academic Medical Centers: Oral vs Intravenous Antibiotics for Diabetic Osteomyelitis
Background: The Infectious Diseases Society of America guidelines recommend a prolonged course of antibiotics in the setting of residual osteomyelitis. More recently published literature suggests that oral antibiotics may offer comparable outcomes to intravenously administered antibiotics when treating orthopaedic infections. In a prior study, we investigated the outcomes of both routes of antibiotic administration in patients with diabetic foot infections at a single academic medical institution. Methods: The goal of this study is to retrospectively evaluate the therapeutic success in 196 patients receiving oral or intravenous antibiotics for treatment of residual infection following amputation at 2 academic medical centers. Treatment was considered successful if patients who completed a minimum of 4 weeks of antibiotic therapy had complete wound healing and did not require additional debridement or amputation within 1 year of their initial surgery. Results: After performing a retrospective chart review, no difference was determined in treatment success between patients who underwent oral or intravenous antibiotics at either WFBMC ( P = .34) or UPMC ( P = .99). No difference in success was found when combining institutional data ( P = .52). The median time to healing for oral antibiotics was 3.21 months compared with 3.85 months for intravenous ( P = .16). Reoperation rates did not differ among treatment types ( P = .53). Hemoglobin A 1c values were lower among patients with treatment success (8.6 ± 2.3) versus failure (9.5 ± 2.5) ( P = .016). Conclusion: This study supports the consideration of oral antibiotics as a viable option for selected diabetic patients with residual osteomyelitis. No significant differences were observed in treatment success, healing time, or reoperation rates, although the study was not powered to determine equivalence.
- 27 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (14) , 1787-1796
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy
Nearly half of patients with cancer are diagnosed at 70 years or older, which presents challenges in cancer care due to their high comorbidity burden and the underrepresentation of this age group in clinical trials. This retrospective study evaluated the association between comorbidity burden and immune checkpoint inhibitors (ICIs) treatment outcomes among older adults. Data were collected from patients aged 70 years or older at the time of diagnosis who were treated with ICIs from 2011 to 2022. Key clinical outcomes include changes in performance status, overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs) and were compared between low baseline Charlson Comorbidity Index (CCI) and high CCI (n = 300) had a significantly shorter OS (11.4 vs. 13.6 months, p = 0.0461) but similar PFS (8.0 vs. 7.7 months, p = 0.258) compared to patients with CCI scores p = 0.14) or in the irAE prevalence between the two groups (39.3% vs. 38.3%, p = 0.786). Our study suggests that ICIs are safe in patients with high comorbidity burden but that the presence of pre-treatment comorbidities decreases overall survival.
- 27 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (14) , 1787-1796
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy
Nearly half of patients with cancer are diagnosed at 70 years or older, which presents challenges in cancer care due to their high comorbidity burden and the underrepresentation of this age group in clinical trials. This retrospective study evaluated the association between comorbidity burden and immune checkpoint inhibitors (ICIs) treatment outcomes among older adults. Data were collected from patients aged 70 years or older at the time of diagnosis who were treated with ICIs from 2011 to 2022. Key clinical outcomes include changes in performance status, overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs) and were compared between low baseline Charlson Comorbidity Index (CCI) and high CCI (n = 300) had a significantly shorter OS (11.4 vs. 13.6 months, p = 0.0461) but similar PFS (8.0 vs. 7.7 months, p = 0.258) compared to patients with CCI scores p = 0.14) or in the irAE prevalence between the two groups (39.3% vs. 38.3%, p = 0.786). Our study suggests that ICIs are safe in patients with high comorbidity burden but that the presence of pre-treatment comorbidities decreases overall survival.
- 29 March 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108513
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status
- 29 March 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108513
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status
- 8 February 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (3) , 358-359
Association between circulating ketone bodies and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA)
- 8 February 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (3) , 358-359
Association between circulating ketone bodies and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA)
- Open Access
- 27 July 2024
- Published by Elsevier in Foot & Ankle Surgery: Techniques, Reports & Cases
- Vol. 4 (3)
The advantages of a dual incisional approach for talonavicular joint preparation: A cadaveric comparison study
- 27 July 2024
- Published by Elsevier in Foot & Ankle Surgery: Techniques, Reports & Cases
- Vol. 4 (3)
Open AccessThe advantages of a dual incisional approach for talonavicular joint preparation: A cadaveric comparison study
- 22 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (9) , OP2300729
Multi-Institutional Study of Referral Patterns for Gynecologic Oncology Consultation
PURPOSE Evaluation by a gynecologic oncologist (GO) is associated with improved clinical outcomes for patients with gynecologic cancers, yet little is known about health care factors that influence patients' referrals to GO. METHODS Medical records of 50 consecutive new patients seen in GO clinics at each of six referral centers across the United States were reviewed. Patient and disease characteristics were collected along with referral indication, evaluation and referral dates, diagnostic procedures, provider specialties, and zone improvement plan (ZIP) code of up to three referring providers per patient. The primary outcome was interval between first evaluation and referral. Univariate associations were evaluated with Chi-square and Wilcoxon rank-sum tests and multivariable associations with negative binomial regression models. Secondary outcome was prolonged time to GO referral, defined as greater than the 75th percentile. Logistic regression was used for multivariable modeling. RESULTS Three hundred patient records were analyzed. The median time from first health care encounter to referral was 15 days (IQR, 5-43). The mean distance from residence to GO was 39.8 miles (standard deviation, 53.8). Seventy-one percent of GO referrals were initiated by obstetrician-gynecologists, 9% by family physicians, and 6% internists. Presentation-to-referral interval was 76% shorter for patients evaluated by an emergency medicine clinician (exp(Beta), 0.24; 95% CI, 0.11 to 0.53; P < .001). Public insurance was associated with 1.47 times longer time to referral compared with private insurance (exp(Beta), 1.47; 95% CI, 1.05 to 2.04; P = .001). Residents of nonmetropolitan ZIP codes were less likely to have prolonged time to referral (odds ratio [OR], 0.288; P = .017). Distance from residence to GO (per 10 miles) increased the likelihood of prolonged time to referral (OR, 1.10; P = .010). CONCLUSION Interventions are needed to improve recognition and referral of patients for gynecologic oncology evaluation. Community outreach and engagement with obstetrician-gynecologists should be prioritized to improve times to referral.
- 22 May 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (9) , OP2300729
Multi-Institutional Study of Referral Patterns for Gynecologic Oncology Consultation
PURPOSE Evaluation by a gynecologic oncologist (GO) is associated with improved clinical outcomes for patients with gynecologic cancers, yet little is known about health care factors that influence patients' referrals to GO. METHODS Medical records of 50 consecutive new patients seen in GO clinics at each of six referral centers across the United States were reviewed. Patient and disease characteristics were collected along with referral indication, evaluation and referral dates, diagnostic procedures, provider specialties, and zone improvement plan (ZIP) code of up to three referring providers per patient. The primary outcome was interval between first evaluation and referral. Univariate associations were evaluated with Chi-square and Wilcoxon rank-sum tests and multivariable associations with negative binomial regression models. Secondary outcome was prolonged time to GO referral, defined as greater than the 75th percentile. Logistic regression was used for multivariable modeling. RESULTS Three hundred patient records were analyzed. The median time from first health care encounter to referral was 15 days (IQR, 5-43). The mean distance from residence to GO was 39.8 miles (standard deviation, 53.8). Seventy-one percent of GO referrals were initiated by obstetrician-gynecologists, 9% by family physicians, and 6% internists. Presentation-to-referral interval was 76% shorter for patients evaluated by an emergency medicine clinician (exp(Beta), 0.24; 95% CI, 0.11 to 0.53; P < .001). Public insurance was associated with 1.47 times longer time to referral compared with private insurance (exp(Beta), 1.47; 95% CI, 1.05 to 2.04; P = .001). Residents of nonmetropolitan ZIP codes were less likely to have prolonged time to referral (odds ratio [OR], 0.288; P = .017). Distance from residence to GO (per 10 miles) increased the likelihood of prolonged time to referral (OR, 1.10; P = .010). CONCLUSION Interventions are needed to improve recognition and referral of patients for gynecologic oncology evaluation. Community outreach and engagement with obstetrician-gynecologists should be prioritized to improve times to referral.
- 6 April 2024
- Published by Elsevier in The Journal of Foot and Ankle Surgery
- Vol. 63 (4) , 490-494
Diabetic Osteomyelitis: Oral versus Intravenous Antibiotics at a Single Level 1 Academic Medical Trauma Center
- 6 April 2024
- Published by Elsevier in The Journal of Foot and Ankle Surgery
- Vol. 63 (4) , 490-494
Diabetic Osteomyelitis: Oral versus Intravenous Antibiotics at a Single Level 1 Academic Medical Trauma Center
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Innovation in Aging
- Vol. 7 (Supplement) , 518
LONG-TERM ASSOCIATION OF AN INTENSIVE LIFESTYLE INTERVENTION ON FRAILTY AND MULTIMORBIDITY
Multidomain lifestyle interventions may slow aging as captured by deficit accumulation frailty indices (FIs) and multimorbidity. We previously reported that the 10-year Look AHEAD multidomain intensive lifestyle intervention (ILI) that focused on caloric restriction, increased physical activity, improved diet, and cardiometabolic risk factor monitoring, significantly slowed the progression of both FI and a multimorbidity index during intervention delivery. We assessed whether these benefits endured after ILI delivery was terminated and the degree to which these benefits may be interrelated. The Look AHEAD Aging study enrolled N=1606 individuals, ages 63-94 years, who had been assigned a median of 20 years earlier (i.e., 10 years after ILI was terminated) to either the Look AHEAD ILI or its control condition of diabetes support and education (DSE). At the original Look AHEAD randomization, they had a mean (SD) 39-component FI score of 0.128 (0.056) and mean (SD) 9-component multimorbidity index of 1.63 (1.01), both balanced across intervention groups. When enrolled in the Look AHEAD Aging study, participants who had been assigned to ILI, compared with those assigned to DSE, averaged 6% lower FI scores (p<0.0001). They had also accrued 0.14 fewer additional age-related chronic diseases from baseline (p<0.0001). Relative benefits associated with ILI for these indices were similar for both genders and across the full cohort’s age range. Increases in FI and multimorbidity were highly correlated (r=0.55; p<0.001), similarly in both arms. Multidomain lifestyle interventions can result in persistent long-term benefits in two common markers of aging.
- 1 December 2023
- Published by Oxford University Press (OUP) in Innovation in Aging
- Vol. 7 (Supplement) , 518
Open AccessLONG-TERM ASSOCIATION OF AN INTENSIVE LIFESTYLE INTERVENTION ON FRAILTY AND MULTIMORBIDITY
Multidomain lifestyle interventions may slow aging as captured by deficit accumulation frailty indices (FIs) and multimorbidity. We previously reported that the 10-year Look AHEAD multidomain intensive lifestyle intervention (ILI) that focused on caloric restriction, increased physical activity, improved diet, and cardiometabolic risk factor monitoring, significantly slowed the progression of both FI and a multimorbidity index during intervention delivery. We assessed whether these benefits endured after ILI delivery was terminated and the degree to which these benefits may be interrelated. The Look AHEAD Aging study enrolled N=1606 individuals, ages 63-94 years, who had been assigned a median of 20 years earlier (i.e., 10 years after ILI was terminated) to either the Look AHEAD ILI or its control condition of diabetes support and education (DSE). At the original Look AHEAD randomization, they had a mean (SD) 39-component FI score of 0.128 (0.056) and mean (SD) 9-component multimorbidity index of 1.63 (1.01), both balanced across intervention groups. When enrolled in the Look AHEAD Aging study, participants who had been assigned to ILI, compared with those assigned to DSE, averaged 6% lower FI scores (p<0.0001). They had also accrued 0.14 fewer additional age-related chronic diseases from baseline (p<0.0001). Relative benefits associated with ILI for these indices were similar for both genders and across the full cohort’s age range. Increases in FI and multimorbidity were highly correlated (r=0.55; p<0.001), similarly in both arms. Multidomain lifestyle interventions can result in persistent long-term benefits in two common markers of aging.